The use of Cannabidiol as a Non-Conventional Therapy in the control of epileptic seizures
DOI:
https://doi.org/10.33448/rsd-v13i12.47614Keywords:
Cannabidiol; Epilepsy; Anticonvulsants; Medicinal marijuana; Therapeutic uses.Abstract
Cannabidiol (CBD) or medicinal cannabis is used as a non-conventional therapy in epilepsy since treatment with anticonvulsant drugs and their combinations do not have the necessary effectiveness, as these alone do not control seizures. Epilepsy is caused by a temporary and reversible modification of the brain and is classified as generalized, focal, combined focal, and unknown epilepsy. Treatment with various medications does not result in seizure control, known as TRE (Treatment-Resistant Epilepsy), therefore, other possibilities have emerged, such as CBD. The objective of this review is to provide knowledge on the use of medicinal cannabis as an integrative therapy in epilepsy, based on pre-established studies and trials in epileptic patients treated with CBD, its adverse effects, efficacy, and safety. Coming from the Cannabis sativa L. plant, it is possible to extract cannabidiol and tetrahydrocannabinol (THC), the first does not have psychoactive action, while the second has hallucinogenic action, therefore, only concentrations lower than 0.2 are allowed in pharmaceutical formulations. % of THC, as it is a stimulating substance, its main effects being the sensation of relaxation, euphoria, and disfigurement of the perception of time; in addition to physical changes, including red eyes, and increased appetite.
References
Asra Fazlollahi, Mahdi Zahmatyar, Mahta ZareDini, Behnam Golabi, Seyed Aria Nejadghaderi, Sullman, M. J. M., Koroush Gharagozli, Ali-Asghar Kolahi, & Saeid Safiri. (2023). Adverse Events of Cannabidiol Use in Patients With Epilepsy. JAMA Network Open, 6(4), e239126–e239126. https://doi.org/10.1001/jamanetworkopen.2023.9126.
Bola Adamolekun. (2024, 4 de janeiro). Anticonvulsivantes. Manuais MSD Edição Para Profissionais; Manuais MSD. https://www.msdmanuals.com/pt/profissional/dist%C3%BArbios-neurol%C3%B3gicos/transtornos-convulsivos/anticonvulsivantes.
Brasil. (2022). Epilepsia: conheça a doença e os tratamentos disponíveis no SUS. Ministério da Saúde.
Castillo-Arellano, J., Canseco-Alba, A., Cutler, S. J., & León, F. (2023). The Polypharmacological Effects of Cannabidiol. Molecules, 28(7), 3271. https://doi.org/10.3390/molecules28073271.
Casarin, S. T. et al. (2020). Tipos de revisão de literatura: considerações das editoras do Journal of Nursing and Health. Journal of Nursing and Health. 10(5). https://periodicos.ufpel.edu.br/index.php/enfermagem/article/view/19924.
Cavalcante, L. T. C. & Oliveira, A. A. S. (2020). Métodos de revisão bibliográfica nos estudos científicos. Psicol. Rev. 26(1). https://doi.org/10.5752/P.1678-9563.2020v26n1p82-100.
Center. (2024). La FDA pone sobre aviso a empresa que comercializa productos hechos a base de cannabidiol sin sancionar haciendo afirmaciones infundadas de que tratan el cáncer, la enfermedad de Alzheimer, la abstinencia de opiáceos, el dolor y la ansiedad en las mascotas. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/la-fda-pone-sobre-aviso-empresa-que-comercializa-productos-hechos-base-de-cannabidiol-sin-sancionar.
Estado inicia regulamentação de medicamentos à base de canabidiol e tetrahidrocanabinol. (2023). Agência Estadual de Notícias. https://www.aen.pr.gov.br/Noticia/Estado-inicia-regulamentacao-de-medicamentos-base-de-canabidiol-e-tetrahidrocanabinol.
Ferreira, I. de L. M., & Silva, T. P. T. e. (2009). Mortalidade por epilepsia no Brasil, 1980-2003. Ciência & Saúde Coletiva, 14(1), 89–94. https://doi.org/10.1590/s1413-81232009000100014.
Kühne, F., Becker, L., Bast, T., Bertsche, A., Borggraefe, I., Boßelmann, C. M., Fahrbach, J., Hertzberg, C., Herz, N. A., Hirsch, M., Holtkamp, M., Janello, C., Kluger, G. J., Kurlemann, G., Lerche, H., Makridis, K. L., von Podewils, F., Pringsheim, M., Schubert‐Bast, S., & Schulz, J. (2023). Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. Epilepsia Open. https://doi.org/10.1002/epi4.12699.
LBE. (2024). O que é epilepsia. Liga Brasileira de Epilepsia - LBE. https://www.epilepsia.org.br/o-que-e.
Martinez Naya, N., Kelly, J., Corna, G., Golino, M., Polizio, A. H., Abbate, A., Toldo, S., & Mezzaroma, E. (2024). An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects. Molecules (Basel, Switzerland), 29 (2), 473. https://doi.org/10.3390/molecules29020473.
Rother, E. T. (2007). Revisão sistemática x revisão narrativa. Acta Paul. Enferm. 20(2). https://doi.org/10.1590/S0103-21002007000200001.
Torres, N. C. (2023). O uso do canabidiol como terapia alternativa no tratamento da epilepsia com ênfase na infância: Uma revisão integrativa. Repositório da Universidade Federal do Alagoas (UFAL). Maceió, Alagoas. https://www.repositorio.ufal.br/bitstream/123456789/12428/1/O%20uso%20do%20canabidiol%20como%20terapia%20alternativa%20no%20tratamento%20da%20epilepsia%20com%20%C3%AAnfase%20na%20inf%C3%A2ncia%3A%20uma%20revis%C3%A3o%20integrativa.pdf.
Oliveira de Freitas, Y. (2022). Uso do canabidiol para o tratamento de depressão, epilepsia e Alzheimer. Universidade Unigranrio/AFYA. https://unigranrio.com.br/_docs/biblioteca-virtual/pdfs/cursos/farmacia/TCC_2022_2_Uso-do-Canabidiol-para-o-tratamento-de-Depress%C3%A3o-Epilepsia-e-Alzheimer.pdf.
Oshiro, C. A., & Castro, L. H. M. (2022). Cannabidiol and epilepsy in Brazil: a current review. Arquivos de Neuro-Psiquiatria, 80(5 suppl 1), 182–92. https://doi.org/10.1590/0004-282x-anp-2022-s137.
Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S. & Corsi, L. (2018). Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. BioMed Research International, 2018, 1–15. https://doi.org/10.1155/2018/1691428.
Portela, R., Mota, D. M., Ferreira, P. J. G., Lula, M. D., Reis, B. B., Oliveira, H. N. de, & Ruas, C. M. (2023). Judicialização de produtos à base de canabidiol no Brasil: uma análise de 2019 a 2022. Cadernos de Saúde Pública, 39, e00024723. https://doi.org/10.1590/0102-311XPT024723.
Rosenberg, E. C., Patra, P. H., & Whalley, B. J. (2017). Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy & Behavior, 70, 319–27. https://doi.org/10.1016/j.yebeh.2016.11.006.
Seizure Classification. (n.d.). Epilepsy Diagnosis. https://www.epilepsydiagnosis.org/seizure/seizure-classification-groupoverview.html.
Shane-Mcwhorter, L. (2024). Manual MSD Versão Saúde para a Família. Manual MSD Versão Saúde Para a Família. https://www.msdmanuals.com/pt/casa/assuntos-especiais/suplementos-alimentares-e-vitaminas/canabidiol-cbd.
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P. & Mazzon, E. (2019). Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules, 24 (8), 1459. https://doi.org/10.3390/molecules24081459.
von Wrede, R., Helmstaedter, C. & Surges, R. (2021). Cannabidiol in the Treatment of Epilepsy. Clinical Drug Investigation, 41 (3), 211–220. https://doi.org/10.1007/s40261-021-01003-y.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aline Açuzena Román Palacios; Maytê Vieira Nascimento dos Santos; Paula Sanches Figueiredo; Raquel Silveira Bertoluci; Gustavo José Vasco Pereira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
